Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Disruption of Prepulse Inhibition and Increases in Locomotor Activity by Competitive N-Methyl-d-aspartate Receptor Antagonists in Rats

Vaishali P. Bakshi, Mark Tricklebank, Hans C. Neijt, Virginia Lehmann-Masten and Mark A. Geyer
Journal of Pharmacology and Experimental Therapeutics February 1999, 288 (2) 643-652;
Vaishali P. Bakshi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Tricklebank
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans C. Neijt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia Lehmann-Masten
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Geyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonists such as phencyclidine are psychotomimetics and disrupt prepulse inhibition (PPI), a measure of sensorimotor gating that is deficient in schizophrenia. Systemically administered competitive NMDA receptor antagonists do not disrupt PPI in rats, leading to speculation that these compounds might have use as neuroprotective agents without the risk of psychotomimetic side effects. The effects on sensorimotor gating and locomotor activity of competitive NMDA receptor antagonists that either penetrate (SDZ 220-581 and SDZ EAB-515) or poorly penetrate [SDZ EAA-494 (D-CPPene)] the blood-brain barrier were compared. Rats were treated with either SDZ 220-581 (0, 2.5, or 5.0 mg/kg) or SDZ EAB-515 (0, 3.0, 10.0, or 30.0 mg/kg) and tested for PPI and locomotor activity. Different rats were tested for PPI after either systemic (0, 0.5, 1.0, or 5.0 mg/kg) or intra-amygdala (0 or 1.0 μg/μl) administration of D-CPPene. Finally, rats were pretreated with clozapine (0 or 5.0 mg/kg) or haloperidol (0 or 0.1 mg/kg), together with SDZ 220-581 (0 or 2.5 mg/kg), and tested. SDZ 220-581 and SDZ EAB-515 decreased PPI without affecting startle magnitude. Reduced PPI was noted after central but not systemic administration ofD-CPPene. The gating deficits produced by SDZ 220-581 were blocked by clozapine or haloperidol. Movement pattern analysis indicated that locomotor activity was increased by SDZ 220-581 and SDZ EAB-515 in a phencyclidine-like manner. These results indicate that competitive NMDA receptor antagonists, if they gain sufficient access to the brain, produce a behavioral profile that resembles that of the psychotomimetic noncompetitive antagonists.

Footnotes

  • Send reprint requests to: Dr. Mark A. Geyer, Department of Psychiatry, 0804, University of California at San Diego, La Jolla, CA 92093-0804. E-mail: mgeyer{at}ucsd.edu

  • ↵1 This work was supported in part by Grant R37-MH42228 from the National Institute of Mental Health and Grant R02-DA02925 from the National Institute on Drug Abuse. V.P.B. was supported by Grant F31-MH11636 from the National Institute of Mental Health. M.A.G. was supported by a Research Scientist Award (K05-MH01223) from the National Institute of Mental Health and holds an equity position with San Diego Instruments.

  • Abbreviations:
    NMDA
    N-methyl-d-aspartate
    BPM
    behavior pattern monitor
    PPI
    prepulse inhibition
    ANOVA
    analysis of variance
    NMDA-RA
    N-methyl-d-aspartate receptor antagonist
    PCP
    phencyclidine
    ANOVA
    analysis of variance
    AP-5
    d-2-amino-5-phosphonopentanoic acid
    D-CPPene
    SDZ EAA-494
    AP-7
    d-2-amino-7-phosphonopentanoic acid
    CNS
    central nervous system
    • Received March 18, 1998.
    • Accepted September 1, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 288 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 288, Issue 2
1 Feb 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Disruption of Prepulse Inhibition and Increases in Locomotor Activity by Competitive N-Methyl-d-aspartate Receptor Antagonists in Rats
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Disruption of Prepulse Inhibition and Increases in Locomotor Activity by Competitive N-Methyl-d-aspartate Receptor Antagonists in Rats

Vaishali P. Bakshi, Mark Tricklebank, Hans C. Neijt, Virginia Lehmann-Masten and Mark A. Geyer
Journal of Pharmacology and Experimental Therapeutics February 1, 1999, 288 (2) 643-652;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Disruption of Prepulse Inhibition and Increases in Locomotor Activity by Competitive N-Methyl-d-aspartate Receptor Antagonists in Rats

Vaishali P. Bakshi, Mark Tricklebank, Hans C. Neijt, Virginia Lehmann-Masten and Mark A. Geyer
Journal of Pharmacology and Experimental Therapeutics February 1, 1999, 288 (2) 643-652;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
  • Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals?
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics